Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis

Allergan

Status and phase: Terminated; Phase 2

Conditions: Cystitis, Interstitial

Treatments: Drug: AGN 203818

Study type: Interventional

Funder types: Industry

Identifiers

NCT00380783

203818-005

Details and patient eligibility

About

This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis

Enrollment: 2 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of painful bladder syndrome/interstitial cystitis
• Moderate or severe bladder pain

Exclusion criteria

• Any other uncontrolled disease
• Pregnant or nursing females

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind